UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I ...

First Quarter 2025 May 2025 Earnings Supplement Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward- looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, estimates of our total addressable market, our abi ...

Astrana Health, Inc. (ASTH) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -39.13%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced a loss of $0.15, delivering a surprise of -266.67%.Over the last four quarters, the co ...

Astrana Health (ASTH) Q1 2025 Earnings Call May 08, 2025 05:30 PM ET Speaker0 Good day, everyone, and welcome to today's Astrana Health First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have an opportunity to ask questions during the question and answer session and instructions will be provided at that time. Today's speakers will be Brandon Sim, President and Chief Executive Officer of Astrana Health and Chand Basho, Chief Operating and ...

Exhibit 99.1 Financial Highlights for three months ended March 31, 2025: All comparisons are to the three months ended March 31, 2024 unless otherwise stated. See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information. Recent Operating Highlights • Total revenue of $620.4 million, up 53% from $404.4 million • Care Partners revenue of $601.0 million, up 57% from $382.3 million • Net income attributable to ...

Company to Host Conference Call on Thursday, May 8, 2025, at 2:30 p.m. PT/5:30 p.m. ETALHAMBRA, Calif., May 8, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the first quarter ended March 31, 2025."Astrana's s ...

Company Overview - Astrana Health, Inc. (ASTH) is expected to report a year-over-year decline in earnings of 25.8%, with an estimated EPS of $0.23 for the quarter ended March 2025 [3][12] - Revenue is projected to be $635.17 million, reflecting a significant increase of 57.1% compared to the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on May 8, 2025, and could lead to stock price movements depending on whether the results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised 6.67% higher in the last 30 days, indicating a more optimistic outlook from analysts [4][10] Earnings Surprise Prediction - The Zacks Earnings ESP for Astrana Health is +13.04%, suggesting a higher likelihood of beating the consensus EPS estimate [11] - The company currently holds a Zacks Rank of 3 (Hold), which indicates a moderate outlook [11] Historical Performance - In the last reported quarter, Astrana Health was expected to post earnings of $0.09 per share but instead reported a loss of $0.15, resulting in a surprise of -266.67% [12] - Over the past four quarters, the company has only beaten consensus EPS estimates once [13] Industry Context - In the Zacks Medical - Outpatient and Home Healthcare industry, Elanco Animal Health Incorporated (ELAN) is also expected to report earnings, with an EPS estimate of $0.31, reflecting a year-over-year decline of 8.8% [17] - Elanco's revenue is anticipated to be $1.17 billion, down 3.1% from the previous year [17]

Earnings Supplement February 2025 Fourth Quarter & Full Year 2024 .&. Astrana Health Forward Looking Statements This consectation contains for ward-locking statements within the measing of the Pivate Securities Litigation Reform Act of 1995. Section 274 of the Securities Aut and Sec looking statements indude any statements about the Company los business. fifrancial condition, operating results, plans objectives, expectation sandi ritertions, expansion market, our ability to successfully complete and realize ...

Financial Data and Key Metrics Changes - In Q4 2024, total revenue reached $665.2 million, an 88.4% increase year-over-year, while adjusted EBITDA was $35 million, reflecting a 20.8% growth [16][33] - For the full year 2024, total revenue was $2.03 billion, a 47% increase from 2023, with adjusted EBITDA of $170.4 million, up 16.2% year-over-year [16][33] Business Line Data and Key Metrics Changes - The Care Partners segment grew 52% year-over-year to $1.95 billion, driving overall growth despite significant strategic investments that impacted earnings by approximately $13 million [17][34] - Membership in the Care Partner segment increased by 55%, attributed to the conversion of CFC and the acquisition of CHS [19] Market Data and Key Metrics Changes - By the end of 2024, approximately 73% of total capitation revenue came from full risk arrangements, with expectations for continued growth in this area [20] - The company experienced a 5.3% utilization trend across all lines of business, significantly lower than the national average [23] Company Strategy and Development Direction - The company focuses on four strategic pillars: sustainable membership growth, responsible risk progression, improving patient outcomes, and operational excellence through the Care Enablement platform [10][24] - Significant investments in automation and AI are planned to enhance efficiency and scalability, with expected operational efficiencies of approximately $10 million by early 2026 [25][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive sustainable profitable growth despite a complex macroeconomic environment [41] - The guidance for 2025 anticipates revenues between $2.5 billion and $2.7 billion, with adjusted EBITDA projected between $170 million and $190 million [41][42] Other Important Information - The company is working closely with Prospect Health Systems, which filed for Chapter 11 bankruptcy, to ensure the acquisition's timeline remains unaffected [37] - The company plans to file a Form 12b-25 to extend the deadline for its annual report due to delays in finalizing financial information related to acquisitions [45] Q&A Session Summary Question: Can you dive deeper into the adjusted EBITDA guidance? - Management indicated that the margin was down due to ongoing investments and the impact of CHS, with a consistent trend assumed for 2025 [49][50] Question: What is the expected free cash flow for this year? - Free cash flow was impacted by one-time items in 2024, but a recovery is expected in 2025, with a higher percentage of free cash flow anticipated [52] Question: How will Medicaid reimbursement cuts impact the business? - Management believes that having most Medicaid membership in California provides some insulation, but no reimbursement increases are assumed in the guidance [70][71] Question: What are the expected margins for Prospect at maturity? - Expected margins for Prospect are projected to be in the low to mid-single digits, with significant potential for growth in fully capitated revenue [129][130] Question: Can you elaborate on the operational playbook for new markets? - The company aims to achieve break-even in new markets by reaching around 10,000 Medicare equivalent memberships, which supports the necessary infrastructure [139]

Company Performance - Astrana Health, Inc. reported a quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of $0.09, and a decline from earnings of $0.26 per share a year ago, representing an earnings surprise of -266.67% [1] - The company posted revenues of $665.21 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 5.42%, and showing significant growth from year-ago revenues of $353.04 million [2] - Over the last four quarters, Astrana Health has surpassed consensus revenue estimates three times, but has only exceeded EPS estimates once [2] Stock Outlook - Astrana Health shares have increased approximately 11.3% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.34 on revenues of $574.8 million, and for the current fiscal year, it is $1.41 on revenues of $2.56 billion [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Astrana Health belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5] Estimate Revisions - The estimate revisions trend for Astrana Health is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6]